|
|
 |
|
Viewing report
|
|
|
|
Prostate Cancer Drug Futures 2010
Espicom Business Intelligence Ltd, Oct 2010, Pages: 214
The prostate cancer (PC) market is on the verge of considerable change with the imminent arrival of new targeted therapies that will prolong patient survival. PC is the second leading cause of new cancer cases in men worldwide and the sixth leading cause of cancer death in men. In the US, over two million men currently suffer with PC and it is estimated that there were 192,311 new cases and 29,698 deaths due to the disease in 2008. There have been dramatic improvements in PC survival over the last 25 years, mainly due to a combination of earlier diagnosis and improvements in treatments, although rates vary between countries
The PC market was estimated to be worth US$5.2 billion in 2008; it is one of the larger segments of the oncology market, alongside breast, non-small cell lung and colorectal cancers. The market is currently driven by the use of hormonal therapies, which are prescribed mainly for advanced hormone-dependent PC. However, the market dynamics will change considerably over the next six years as patents expire and generic competition intensifies. Research into new therapies is extremely active and new agents with novel modes of action are being evaluated.
NOW YOU CAN STAY IN TOUCH WITH THE DEVELOPMENTS WHICH MATTER
This all new web service, Prostate Cancer Drug Futures, assesses the future prospects for market success for individual drugs. Based on independent research and proprietary analysis, each product assessed brings the prospects for a product into clear focus. Best of all, each drug is regularly reviewed ensuring that latest developments are incorporated for you to see.
WITH EACH KEY DRUG ANALYSED IN THIS SERVICE YOU CAN:
- Track the drug’s progress and stay abreast of developments
- Understand the drug’s novelty and mode of action
- Evaluate the strength of the company developing/producing the drug
- Review opportunities and challenges with Espicom’s unique 5-point competitive assessment
- Know the launch timeframe for new products or indications
- Be aware of promising mid-stage development candidates
- Estimate future revenues with original 5-year forecasts for launched and leading pipeline candidates
- Review significant clinical trial results
STRUCTURED ANALYSIS OF KEY DRIVERS AND DAMPENERS OF SUCCESS
For each product analysed there is an extensive and standardised review of the factors which can affect its clinical and commercial performance. Those factors include:
- Novelty/rationale for mechanism of action
- Current status
- Proof of concept/clinical data
- Development risks
- Company expertise
- Competition within the market-place
- Sales forecast (for key late-stage and launched products)
- Competitor ratio analysis score
- Clinical trial results
OVER 45 PROSTATE DRUGS INCLUDE:
Because this service is continually updated, products will be added, deleted or enhanced in response to ongoing developments throughout the course of your licence. From time-to-time drug profiles may be removed from the service for essential updating.
- Approved
- Bicalutamide
- Cabazitaxel
- Degarelix
- Docetaxel
- Goserelin
- Leuprorelin
- Mitoxantrone
- Paclitaxel
- Sipuleucel-T
- Filed
- Dutasteride
- Phase III
- Abiraterone acetate
- Aflibercept
- Dasatinib
- Ipilimumab
- Radium-223
- ZD4054
- Phase II
- AT-101
- Bortezomib
- Cixutumumab
- E75 GM-CSF adjuvant vaccine
- Enzastaurin
- Figitumumab
- Ixabepilone
- OGX-011
- OnyVax-P
- PROSTVAC
- Ramucirumab
- Sagopilone
- Vadimezan
CLEAR, CONCISE, AND ORIGINAL ANALYSIS GIVES YOU KEY PRODUCT INSIGHTS
The Cancer Drug Futures incorporate the latest analysis from our in-house team of life scientists and statisticians across a range of cancer areas. Their research builds upon the analysts established knowledge base of up-to-date intelligence on thousands of pharmaceutical manufacturers and research companies, backed up by a fifteen years’ of archive material.
Taking all aspects of the market into account, from clinical trials, deals and alliances to company financial performance and drug sales, the analysis and forecasting that contributes to the analysts Cancer Drug Futures is standardised across each individual launched product or drug candidate and is founded upon a diligent and thorough research process.
With the Cancer Drug Futures you can easily evaluate the prospects of the drugs of interest to you and discover its progress in each indication. Each report provides individual and highly-detailed analysis of the drug, looking at the key factors affecting its future performance in the marketplace.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Breast Cancer Drug Futures 2010
Colorectal Cancer Drug Futures 2010
Lung Cancer Drug Futures 2010
Renal Cell Carcinoma Cancer Drug Futures 2010
Cancer Drug Blockbusters to 2016
Will Anyone Crack the Obesity Drug Market?
Multiple Sclerosis Drug Discoveries - What the Future Holds
Ophthalmology Drug Futures: Sight Preservation in Chronic Eye Diseases
MRSA Drug Futures
Threats to Avastin - Targeting the VEGF Pathway
|
|
|
|
